Medicinal Cannabis and Central Nervous System Disorders

Abstract

Cannabinoids, including those found in cannabis, have shown promise as potential therapeutics for numerous health issues, including pathological pain and diseases that produce an impact on neurological processing and function. Thus, cannabis use for medicinal purposes has become accepted by a growing majority. However, clinical trials yielding satisfactory endpoints and unequivocal proof that medicinal cannabis should be considered a frontline therapeutic for most examined central nervous system indications remains largely elusive. Although cannabis contains over 100 + compounds, most preclinical and clinical research with well-controlled dosing and delivery methods utilize the various formulations of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two most abundant compounds in cannabis. These controlled dosing and delivery methods are in stark contrast to most clinical studies using whole plant cannabis products, as few clinical studies using whole plant cannabis profile the exact composition, including percentages of all compounds present within the studied product. This review will examine both preclinical and clinical evidence that supports or refutes the therapeutic utility of medicinal cannabis for the treatment of pathological pain, neurodegeneration, substance use disorders, as well as anxiety-related disorders. We will predominately focus on purified THC and CBD, as well as other compounds isolated from cannabis for the aforementioned reasons but will also include discussion over those studies where whole plant cannabis has been used. In this review we also consider the current challenges associated with the advancement of medicinal cannabis and its derived potential therapeutics into clinical applications.

Supporting Machine Learning Model in the Treatment of Chronic Pain

“…Although there is strong evidence that cannabinoids are effective in treating rheumatic disease and central nervous system disorders, the clinical evidence remains lacking and has not progressed significantly over the last few years. Clinical trials that provide positive endpoints and evidence that medicinal cannabis should be considered a frontline therapeutic remain largely elusive [37,38]. Similarly, the long-term effects of cannabis in treating spinal disorders are poorly understood.…”

Expression of mRNA encoding two gain-of-functioncyfip2variants associated with DEE65 results in spontaneous seizures inXenopus laevistadpoles

“…2019)). Cannabidiol (CBD) is now approved for use in refractory epilepsy such as Dravet and Lennox-Gastaut syndrome (O rtiz et al . 2022; P agano et al .…”

“…It is not yet known if early seizure control can change the developmental trajectory of children with DEE65, but recent reports have 14 suggested that the GABA transaminase inhibitor vigabatrin may be a good choice to control infantile spasms (infant with Arg87Leu), (ZHONG et al 2019)). Cannabidiol (CBD) is now approved for use in refractory epilepsy such as Dravet and Lennox-Gastaut syndrome (ORTIZ et al 2022;PAGANO et al 2022), both of which now fall under the DEE umbrella diagnostic term. There has been one report of a three year old child with DEE65 (R87C) becoming seizure free with CBD (DE GOES et al 2022).…”

Exploring Cannabis sativa L for Anti-Alzheimer Potential: An extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments

“…Many investigations have examined the potential bene ts of cannabis in addressing neurodegenerative diseases that affect cognitive abilities [20][21][22][23][24][25][26]. Additionally, the neuroprotective effect of this plant is widely studied and proven [27].…”